Clinical trial NCT03592264: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Official title: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Solid Tumor
Pancreatic Adenocarcinoma
Lead sponsor: OBI Pharma, Inc
Sponsor class: INDUSTRY
First posted: 2018-07-19
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.


Eligibility criteria: Inclusion Criteria (all subjects):

1. At least 18 years of age
2. Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
3. Recovered from toxicities of prior therapy to Grade 0 or 1
4. Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) criteria
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
6. Acceptable liver function:

   1. Bilirubin ≤1.5 × institutional ULN
   2. AST and ALT ≤3.0 × ULN, or ≤5.0 × ULN for subjects with liver involvement
7. Acceptable renal function:

   a. Creatinine clearance \>30 mL/min according to the Cockcroft-Gault formula
8. Acceptable hematologic status (without hematologic support, other than red blood cell transfusion):

   1. ANC ≥1500 cells/μL
   2. Platelet count ≥100,000/μL
   3. Hemoglobin ≥9.0 g/dL (prior packed red blood cell transfusion or erythropoietin support is allowed).
9. Females of childbearing potential must not have had unprotected sexual intercourse within 30 days before study entry and must agree to use a highly effective method of contraception (e.g., total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 30 days after study drug discontinuation.

   Dose Escalation Phase Subjects Only (Inclusion Criteria):
10. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
11. Tumor progression after most recent therapy

    Expansion Phase Subjects Only (Inclusion Criteria):
12. Available tumor tissue, either archival or fresh (fresh preferred).
13. For treatment, an AKR1C3 IHC H-score of ≥ 100 using a validated IHC assay in one of the following tumor types to be enrolled in the respective cohort:

    1. Cohort A: Pancreatic Adenocarcinoma
    2. Cohort B: Basket (any solid tumor type other than pancreatic adenocarcinoma)

Exclusion Criteria:

1. Prior radiotherapy to more than 25% of the bone marrow
2. Symptomatic brain metastases, unless previously treated and well controlled for at least 4 weeks after central nervous system (CNS)-directed treatment as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\]) during the Screening Period. Patients with known leptomeningeal disease are excluded.
3. Previously treated malignancies, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancers whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the current study
4. Patients with hepatocellular carcinoma (applies to Expansion Phase only)
5. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
6. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
7. Treatment with radiation therapy, surgery, chemotherapy, targeted therapies or hormones within 3 weeks prior to study entry (6 weeks for nitrosoureas or mitomycin C)
8. Concomitant use of strong CYP3A4 inhibitors/inducers
9. Concomitant use of naproxen within a 48-hour window before and after OBI-3424 dosing
10. Females who are pregnant or breast-feeding
11. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
12. Unwillingness or inability to comply with the study protocol for any reason

Primary outcomes:
measure: Incidence and severity of adverse events (AEs)
timeFrame: Adverse events will be noted as it occurs. Timeframe for measure begins after first administration of study drug until 30 days after last dose of study drug. Study duration defined as up to 2 years from the first dose.
measure: Assess safety changes in electrocardiogram (ECG)
timeFrame: Day 1 Cycles 1 and 2 (each cycle is 21 days)
measure: Assess safety changes of body weight.
timeFrame: Day 1 of each cycle (there are 34 cycles; 21 days for each cycle)
measure: Number of participants with dose limiting toxicities (DLTs)
timeFrame: Throughout Cycle 1 (21 days for each cycle)
measure: Define the Recommended Phase 2 Dose (RP2D)
timeFrame: Days 1 and 8 of each cycle (all 34 cycles and there are 21 days for each cycle)
measure: Pharmacokinetics (PK) - Time to maximum concentration (Tmax)
timeFrame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
measure: PK - Maximum peak plasma concentration (Cmax)
timeFrame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
measure: PK - The magnitude of the slope of the linear regression of the log concentration vs. time profile during the terminal phase (Kel)
timeFrame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
measure: PK - Half-life (T1/2)
timeFrame: Days 1 and 8 of Cycle 1 (first cycle of 34 cycles and there are 21 days for each cycle)
measure: PK - Area under the concentration-time curve (AUClast)
timeFrame: Days 1 and 8 of Cycle 1 (Cycle 1 is 21 days)
Secondary outcomes:
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Clinic Torrey Pines
state: California
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center
state: California
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute of New Jersey
state: New Jersey
city: Columbus
country: United States
facility: Ohio State University Comprehensive Cancer Center
state: Ohio
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Apostolia Tsimberidou, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References: